Johns Hopkins University CRS*

Baltimore, Maryland 21287

0 studies enrolling now · 25 studies all time

What they study most

COVID-19, Cardiovascular Diseases, HIV, HIV Infection, HIV Infections, HIV-1, Hepatitis B, Hepatitis C, Liver Disease, MPOX, Non-Alcoholic Fatty Liver Disease, SARS-CoV-2

Studies at this site

• CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR — Completed
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE — Running, not enrolling
• Study of Tecovirimat for Human Mpox Virus — Stopped early
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men — Completed
• Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy — Paused
• Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 — Completed
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults — Completed
• B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B — Completed
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 — Completed
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) — Completed
• A Study of Immune Responses to the Virus That Causes COVID-19 — Completed
• Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) — Completed
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) — Completed
• Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) — Completed
• Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults — Completed
• Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women — Completed
• Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin — Completed
• Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy — Stopped early
• Optimizing Treatment for Treatment-Experienced, HIV-Infected People — Completed
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection — Completed
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women — Completed
• Intensive Viral Dynamics Substudy of A5248 — Completed
• Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications — Completed
• Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) — Completed
• Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women — Completed